Capecitabine
Tóm tắt
After completing this course, the reader will be able to: Identify the main toxicity profile associated with capecitabine therapy.Identify the main clinical indications for capecitabine therapy.Identify the populations at risk for severe toxicity from capecitabine therapy.
CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Từ khóa
Tài liệu tham khảo
Xu, 2003, Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma, J Chromatogr B Biomed Appl, 783, 273, 10.1016/S1570-0232(02)00674-8
Twelves, 1998, Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites, Clin Cancer Res, 4, 941
Beijnen, 2004, Drug interactions in oncology, Lancet Oncology, 5, 689, 10.1016/S1470-2045(04)01528-1
Giescke, 2003, Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients, Br J Clin Pharmacol, 55, 252, 10.1046/j.1365-2125.2003.01765.x
Raida, 2001, Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls, Clin Cancer Res, 7, 2832